Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must not have had prior chemotherapy for advanced or metastatic disease. Patients could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy.~2. Patient with mCRC for whom bio-chemotherapy is indicated.~3. Patients must have at least one measurable non-irradiated site of disease according to RECIST (version 1.1) criteria. If the patient has had previous irradiation of the marker lesion(s), there must be evidence of progression since the radiation.~4. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy~5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.~6. Adequate bone marrow function~7. Adequate liver function defined within specific parameters~8. Adequate renal function defined within specific parameters~9. Adequate coagulation parameters defined within specific parameters~10. Negative pregnancy test for females of a childbearing potential.~11. Use of an effective form of contraception during the study (for subjects of childbearing potential and their partners).~12. Life expectation ≥ 3 months~Exclusion Criteria:~1. Prior treatment for advanced or metastatic colorectal cancer.~2. Prior treatment with an anti-angiogenesis agent, in either the neoadjuvant or adjuvant setting.~3. Concurrent use of investigational anti-neoplastic agents (including up to 4 weeks prior to enrolment).~4. History of any other malignancy unless the malignancy is in complete remission and the patient has been off all therapy for that malignancy for at least 5 years.~5. Chronic treatment with systemic steroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed.~6. Scheduled immunization with attenuated live vaccines during study period or within 1 week prior to study entry.~7. Uncontrolled brain or lepto-meningeal metastases, including patients who continue to require glucocorticoids for brain or lepto-meningeal metastases.~8. Patients with active bleeding or history of bleeding diathesis on oral anti-vitamin K medication (except low dose coumadin) within the past 6 month prior to randomization or coagulopathy.~9. Patients with history of cerebral vascular accident, transient ischemic attack, or subarachnoid haemorrhage within the past 6 month prior to randomization.~10. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study~11. Patients with serious non-healing wound, ulcer, bone fracture, or with a major surgical procedure, or significant traumatic injury within 4 weeks prior to randomization~12. Patients with clinical symptoms or signs of gastrointestinal obstruction that require parenteral hydration and/or nutrition.~13. Patients with history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months prior to randomization.~14. Patients with history of hypersensitivity to any of the study drugs or ingredients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab biosimilar (BEVZ92) (Type: EXPERIMENTAL): Bevacizumab 25 mg/mL (strength: 100 mg/4 mL).
- Avastin® (bevacizumab, ref. product) (Type: ACTIVE_COMPARATOR): Bevacizumab 25mg/ml (strength: 100mg/4ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete